Skip to content
Inciteful Med
Resources About us Ask a Question

The Trifecta: How EDS, POTS, and MCAS Are Connected

Published: | Updated:

The connection between EDS, POTS, and MCAS is rooted in faulty connective tissue. Weak structural tissue allows blood to pool when standing, causing the rapid heart rate and dizziness of POTS. This same mechanical stress constantly irritates immune cells, triggering allergic-like reactions of MCAS.

Key Takeaways

  • • The frequent overlap of Ehlers-Danlos Syndrome (EDS), POTS, and MCAS is driven by generalized weakness in the body's connective tissue.
  • • Stretchy blood vessels in EDS cause blood to pool when standing, triggering the rapid heart rate and dizziness characteristic of POTS.
  • • Connective tissue laxity makes the digestive tract floppy, causing motility issues like severe bloating, constipation, and diarrhea.
  • • Mechanical stress from weak connective tissue constantly irritates mast cells, causing them to release chemicals that drive MCAS symptoms.
  • • Treating MCAS with antihistamines and mast cell stabilizers reduces inflammation and helps prevent further breakdown of connective tissue.

It can be incredibly frustrating to deal with joint dislocations, dizzy spells, and digestive issues all at once. The connection between Ehlers-Danlos Syndrome (EDS), Postural Orthostatic Tachycardia Syndrome (POTS - a condition causing a rapid heart rate and dizziness when standing), and Mast Cell Activation Syndrome (MCAS - an immune condition causing widespread allergic-style reactions) is often referred to by patients and doctors as the “trifecta.” [1][2][3]

While having one of these conditions does not absolutely guarantee you will have the others, they frequently cluster together. The root link connecting these seemingly distinct symptoms is the faulty biological “glue” that holds your body together: your connective tissue.

The Role of the Extracellular Matrix

Your body’s cells sit inside a scaffolding called the extracellular matrix (ECM), a 3D network of proteins (like collagen) that provides physical and biochemical support to all your tissues. [4][5] In EDS, the structural integrity of this ECM is disrupted, meaning your connective tissue cannot properly support your organs, blood vessels, and joints. [6][7]

How this structural weakness shows up depends largely on your specific EDS subtype. While most subtypes are tied to specific genetic mutations affecting the ECM, they impact the body differently:

  • Hypermobile EDS (hEDS): This is the subtype most frequently associated with the EDS-POTS-MCAS trifecta, driving chronic joint hypermobility and widespread systemic symptoms. [1][3] Unlike other subtypes, the exact genetic marker for hEDS is still being researched, so it is diagnosed clinically based on your symptoms and physical exam. [8]
  • Classical EDS (cEDS): Involves mutations in type V collagen (COL5A1), primarily impacting skin elasticity and joint stability. [6][7]
  • Vascular EDS (vEDS): Affects type III collagen (COL3A1), weakening the walls of blood vessels and hollow organs. This subtype requires specialized cardiac and vascular monitoring to prevent serious complications. [9][6]
  • Classical-like EDS (clEDS), Spondylodysplastic EDS (spEDS), and Dermatosparaxis EDS (dEDS): These rarer subtypes involve other defective ECM components (like dermatan sulfate) rather than traditional collagen, showing that EDS can affect many different parts of your body’s scaffolding. [10][11]

Why Stretchy Connective Tissue Causes Dizziness (POTS)

To keep blood flowing normally to your brain when you stand up, the blood vessels in your legs have to squeeze tightly against gravity. Because blood vessels rely heavily on connective tissue for their structure, in EDS, these vessel walls are often overly lax and stretchy. [12][13]

When you stand, the elastic veins stretch out, allowing blood to pool in your lower body instead of returning to your heart. [14][12] To compensate for the reduced blood return, your nervous system triggers your heart to beat much faster (tachycardia) to keep blood pumping to your brain. [12][15] This sudden, rapid heart rate is the hallmark of POTS and is what causes you to feel lightheaded, dizzy, or faint. [14]

Why the GI Tract Slows Down (or Speeds Up)

Your digestive tract is essentially a long, muscular tube held together by connective tissue. Just as laxity affects your joints and veins, it also makes the walls of the gastrointestinal (GI) tract “floppy.” This structural weakness makes it harder for the stomach and intestines to propel food forward normally, leading to dysmotility (uncoordinated movement of the digestive system). [16][17]

Dysmotility exists on a spectrum—it can mean food moves too slowly (causing severe bloating, acid reflux, and constipation), too quickly (causing diarrhea), or alternating between both. [16][18] This physical floppiness, combined with the autonomic nervous system dysfunction seen in POTS, makes GI issues incredibly common in the EDS population. [18][19]

How the Immune System Gets Involved (MCAS)

Mast cells are immune cells that live directly inside your connective tissues, where they act as guards against injury or infection. [20][21] Emerging research suggests that the constant mechanical stress, subluxations, and unbalanced remodeling of the faulty ECM in EDS chronically irritates these local mast cells. [22][23]

Once triggered, these hyper-reactive mast cells release inflammatory chemicals (like histamine and tryptase) into the surrounding tissues. [24][20] This causes allergic-like systemic symptoms (such as flushing, GI distress, and fatigue), and these chemicals can actually further degrade the structural integrity of the ECM. [24][23] This creates a feedback loop: fragile connective tissue physically irritates mast cells, which release chemicals that further break down the connective tissue. [22][25]

Breaking the Loop: While this feedback loop sounds intimidating, understanding it is incredibly empowering. This is exactly why targeted MCAS treatments—like antihistamines and mast cell stabilizers—are so important. By calming the mast cells, these medications help break the cycle of inflammation, which can help protect your connective tissue and reduce widespread pain. [1][26]

Moving Forward

Understanding this biological mechanism is vital. It proves your symptoms are not isolated or “in your head,” but interconnected results of the same underlying connective tissue vulnerability. Because these conditions overlap so heavily, finding a multidisciplinary care team—including cardiology, gastroenterology, and immunology—is the most effective way to address the whole picture. [1][27]

Frequently Asked Questions

Why do EDS, POTS, and MCAS often occur together?
They frequently cluster together because they share a root cause: weak connective tissue. Faulty connective tissue in Ehlers-Danlos Syndrome makes blood vessels overly stretchy, contributing to POTS, and physically irritates immune cells, triggering MCAS.
How does Ehlers-Danlos Syndrome cause dizziness and POTS?
In EDS, blood vessels are often overly lax and stretchy due to faulty connective tissue. When you stand up, blood pools in your lower body, causing your nervous system to trigger a rapid heart rate to pump blood to your brain, which leads to dizziness and fainting.
Why do people with the EDS trifecta have severe digestive issues?
The gastrointestinal tract is a muscular tube that relies on connective tissue for its structure. In EDS, this tissue laxity makes the digestive walls floppy, leading to uncoordinated movement that can cause severe bloating, acid reflux, constipation, or diarrhea.
How are mast cells involved in the EDS and POTS trifecta?
Mast cells live directly inside your connective tissues. The constant physical stress and stretching from faulty connective tissue in EDS chronically irritates these cells, causing them to release inflammatory chemicals that trigger allergic-like reactions.
Can treating MCAS help with EDS joint pain?
Yes, targeted treatments like antihistamines and mast cell stabilizers can help. Calming the mast cells reduces the release of inflammatory chemicals that break down connective tissue, which can help protect your joints and reduce widespread pain.

Questions for Your Doctor

  • • Given that my connective tissue laxity contributes to POTS, what non-pharmacological strategies (like specific compression garments or hydration goals) would be most effective for my specific case?
  • • Could my current GI symptoms be related to connective tissue dysmotility, and if so, would prokinetic medications or specific dietary modifications help manage the structural floppiness?
  • • Since unmanaged mast cell activation can exacerbate connective tissue breakdown, should we explore a trial of mast cell stabilizers or adjust my current allergy medications?
  • • Do my specific symptoms suggest I should be evaluated for one of the rarer EDS subtypes (like vEDS or cEDS), or does my clinical presentation most strongly align with hEDS?
  • • How can we better coordinate my care between specialties (e.g., cardiology for POTS, immunology for MCAS) so we are treating the 'trifecta' holistically rather than as isolated problems?

Questions for You

  • • Do you notice any patterns where an increase in one symptom (like an allergic flare) corresponds with a worsening of others (like more joint subluxations or worse dizziness)?
  • • What specific triggers—such as standing for long periods, eating certain foods, or environmental allergies—seem to set off your most bothersome symptoms?
  • • How do your digestive symptoms fluctuate on days when your POTS or joint pain is particularly severe?
  • • Which of these three symptom areas (joints, dizziness/fainting, or allergic/GI reactions) currently impacts your daily quality of life the most?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.

    Aziz Q, Harris LA, Goodman BP, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2025; (23(8)):1291-1302 doi:10.1016/j.cgh.2025.02.015.

    PMID: 40387691
  2. 2

    Comorbidities and neurosurgical interventions in a cohort with connective tissue disorders.

    Ruhoy IS, Bolognese PA, Rosenblum JS, et al.

    Frontiers in neurology 2024; (15()):1484504 doi:10.3389/fneur.2024.1484504.

    PMID: 39931100
  3. 3

    An overview of Ehlers Danlos syndrome and the link between postural orthostatic tachycardia syndrome and gastrointestinal symptoms with a focus on gastroparesis.

    Wu W, Ho V

    Frontiers in neurology 2024; (15()):1379646 doi:10.3389/fneur.2024.1379646.

    PMID: 39268060
  4. 4

    Development of Matrix Metalloproteinases-Mediated Extracellular Matrix Remodeling in Regenerative Medicine: A Mini Review.

    Chen K, Xu M, Lu F, He Y

    Tissue engineering and regenerative medicine 2023; (20(5)):661-670 doi:10.1007/s13770-023-00536-x.

    PMID: 37160567
  5. 5

    Cell-Biomaterial Interactions.

    Deplaigne V, Rochefort GY

    Bioengineering (Basel, Switzerland) 2023; (10(2)) doi:10.3390/bioengineering10020241.

    PMID: 36829735
  6. 6

    Patient-derived extracellular matrix demonstrates role of COL3A1 in blood vessel mechanics.

    Doherty EL, Aw WY, Warren EC, et al.

    Acta biomaterialia 2023; (166()):346-359 doi:10.1016/j.actbio.2023.05.015.

    PMID: 37187299
  7. 7

    A patient with a novel pathogenic variant in COL5A1 exhibiting prominent vascular and cardiac features.

    Lavanya K, Mahtani K, Abbott J, et al.

    American journal of medical genetics. Part A 2022; (188(7)):2192-2197 doi:10.1002/ajmg.a.62745.

    PMID: 35396906
  8. 8

    Exploring pain mechanisms in hypermobile Ehlers-Danlos syndrome: A case-control study.

    De Wandele I, Colman M, Hermans L, et al.

    European journal of pain (London, England) 2022; (26(6)):1355-1367 doi:10.1002/ejp.1956.

    PMID: 35442549
  9. 9

    Ehlers-Danlos syndrome and the risk of spontaneous colonic perforation: clinical insights and surgical implications.

    Gaspar D, Pinheiro JL, Santos A, et al.

    Journal of surgical case reports 2025; (2025(7)):rjaf558 doi:10.1093/jscr/rjaf558.

    PMID: 40717702
  10. 10

    Delineation of musculocontractural Ehlers-Danlos Syndrome caused by dermatan sulfate epimerase deficiency.

    Lautrup CK, Teik KW, Unzaki A, et al.

    Molecular genetics & genomic medicine 2020; (8(5)):e1197 doi:10.1002/mgg3.1197.

    PMID: 32130795
  11. 11

    Critical involvement of ZEB2 in collagen fibrillogenesis: the molecular similarity between Mowat-Wilson syndrome and Ehlers-Danlos syndrome.

    Teraishi M, Takaishi M, Nakajima K, et al.

    Scientific reports 2017; (7()):46565 doi:10.1038/srep46565.

    PMID: 28422173
  12. 12

    Median Arcuate Ligament Syndrome and Its Associated Conditions.

    Huynh DTK, Shamash K, Burch M, et al.

    The American surgeon 2019; (85(10)):1162-1165.

    PMID: 31657316
  13. 13

    Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome.

    Roma M, Marden CL, De Wandele I, et al.

    Autonomic neuroscience : basic & clinical 2018; (215()):89-96 doi:10.1016/j.autneu.2018.02.006.

    PMID: 29519641
  14. 14

    Cardiovascular, autonomic symptoms and quality of life in children with hypermobile Ehlers-Danlos syndrome.

    Hertel AK, Black WR, Lytch A, et al.

    SAGE open medicine 2024; (12()):20503121241287073 doi:10.1177/20503121241287073.

    PMID: 39420997
  15. 15

    Mechanisms underlying reflux symptoms and dysphagia in patients with joint hypermobility syndrome, with and without postural tachycardia syndrome.

    Fikree A, Aziz Q, Sifrim D

    Neurogastroenterology and motility 2017; (29(6)) doi:10.1111/nmo.13029.

    PMID: 28191707
  16. 16

    Association between Ehlers-Danlos syndrome and mast cell activation syndrome: Is there scientific evidence?

    Cuenca-Gómez JA, Dawid-Milner MS, Sánchez-Martínez R

    Revista clinica espanola 2026; (226(2)):502457 doi:10.1016/j.rceng.2026.502457.

    PMID: 41554340
  17. 17

    Mast cell activation disease and immunoglobulin deficiency in patients with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorder.

    Brock I, Prendergast W, Maitland A

    American journal of medical genetics. Part C, Seminars in medical genetics 2021; (187(4)):473-481 doi:10.1002/ajmg.c.31940.

    PMID: 34747107
  18. 18

    The association between Ehlers-Danlos syndrome-hypermobility type and gastrointestinal symptoms in university students: a cross-sectional study.

    Fikree A, Aktar R, Morris JK, et al.

    Neurogastroenterology and motility 2017; (29(3)) doi:10.1111/nmo.12942.

    PMID: 27683076
  19. 19

    Prevalence of joint hypermobility syndromes in pediatric postural orthostatic tachycardia syndrome.

    Boris JR, Bernadzikowski T

    Autonomic neuroscience : basic & clinical 2021; (231()):102770 doi:10.1016/j.autneu.2020.102770.

    PMID: 33388686
  20. 20

    Mechanobiology in the Comorbidities of Ehlers Danlos Syndrome.

    Royer SP, Han SJ

    Frontiers in cell and developmental biology 2022; (10()):874840 doi:10.3389/fcell.2022.874840.

    PMID: 35547807
  21. 21

    Mast cell disorders in Ehlers-Danlos syndrome.

    Seneviratne SL, Maitland A, Afrin L

    American journal of medical genetics. Part C, Seminars in medical genetics 2017; (175(1)):226-236 doi:10.1002/ajmg.c.31555.

    PMID: 28261938
  22. 22

    Sex differences in self-reported symptoms and comorbidities associated with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders: A retrospective study.

    Wilson FC, Zangerle DJ, Darakjian AA, et al.

    Research square 2026; doi:10.21203/rs.3.rs-8310986/v1.

    PMID: 41646353
  23. 23

    RNA-Seq of Dermal Fibroblasts from Patients with Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders Supports Their Categorization as a Single Entity with Involvement of Extracellular Matrix Degrading and Proinflammatory Pathomechanisms.

    Ritelli M, Chiarelli N, Cinquina V, et al.

    Cells 2022; (11(24)) doi:10.3390/cells11244040.

    PMID: 36552803
  24. 24

    Mast cells: a double-edged sword in inflammation and fibrosis.

    Wang X, Zhang P, Tang Y, et al.

    Frontiers in cell and developmental biology 2024; (12()):1466491 doi:10.3389/fcell.2024.1466491.

    PMID: 39355120
  25. 25

    Decoding the Genetic Basis of Mast Cell Hypersensitivity and Infection Risk in Hypermobile Ehlers-Danlos Syndrome.

    Shirvani P, Shirvani A, Holick MF

    Current issues in molecular biology 2024; (46(10)):11613-11629 doi:10.3390/cimb46100689.

    PMID: 39451569
  26. 26

    Patient Interest in the Development of a Center for Ehlers-Danlos Syndrome/Hypermobility Spectrum Disorder in the Chicagoland Region.

    Wagner W, Doyle T, Francomano C, et al.

    Research square 2023; doi:10.21203/rs.3.rs-3034682/v1.

    PMID: 37503006
  27. 27

    A Comprehensive Review: Chronic Pain Sequelae in the Presence of Ehlers-Danlos Syndrome.

    Basem JI, Lin T, Mehta ND

    Current pain and headache reports 2022; (26(12)):871-876 doi:10.1007/s11916-022-01093-z.

    PMID: 36434419

This page explains the biological connection between EDS, POTS, and MCAS for educational purposes only. Always consult your multidisciplinary healthcare team for diagnosis and personalized treatment options.

Stay up to date

Get notified when new research about Ehlers Danlos Syndrome (EDS) is published.

No spam. Unsubscribe anytime.